INDIANAPOLIS — Drugmaker Eli Lilly and Company is claiming two of its drugs significantly reduced COVID-19 hospitalizations and deaths in high-risk patients who were recently diagnosed with the virus.
The company announced results of a phase three trial of patients 12 and older who had mild to moderate cases of the coronavirus.
Lilly’s drug treatment was recently granted emergency use authorization from the FDA only to be used in studies.
It has not been approved yet for the general public. The study found an 87% reduction in the number of patients who had an event while on the treatment versus the group that received a placebo.